Genprex Inc. announced positive preliminary preclinical results for its diabetes gene therapy candidate, GPX-002. The company reported in vivo proof-of-concept data from studies in both mouse and non-human primate models of Type 2 diabetes, demonstrating that GPX-002 was able to rejuvenate exhausted beta cells and normalize glucose levels. These results expand Genprex’s research beyond Type 1 to Type 2 diabetes. The company has not yet indicated when or where these results will be presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA58008) on January 07, 2026, and is solely responsible for the information contained therein.